SK12452003A3 - Derivát fenylheterocyklyléteru ako inhibítor reabsorpcie serotonínu, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje - Google Patents

Derivát fenylheterocyklyléteru ako inhibítor reabsorpcie serotonínu, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje Download PDF

Info

Publication number
SK12452003A3
SK12452003A3 SK1245-2003A SK12452003A SK12452003A3 SK 12452003 A3 SK12452003 A3 SK 12452003A3 SK 12452003 A SK12452003 A SK 12452003A SK 12452003 A3 SK12452003 A3 SK 12452003A3
Authority
SK
Slovakia
Prior art keywords
methyl
mhz
mmol
pyridinyl
methylsulfanyl
Prior art date
Application number
SK1245-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Mavis Diane Adam
Mark David Andrews
Geoffrey Edward Gymer
David Hepworth
Harry Ralph Howard Jr.
Donald Stuart Middleton
Alan Stobie
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK12452003A3 publication Critical patent/SK12452003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1245-2003A 2001-04-11 2002-03-27 Derivát fenylheterocyklyléteru ako inhibítor reabsorpcie serotonínu, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje SK12452003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0109103.2A GB0109103D0 (en) 2001-04-11 2001-04-11 Novel compounds
PCT/IB2002/001032 WO2002083643A1 (en) 2001-04-11 2002-03-27 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors

Publications (1)

Publication Number Publication Date
SK12452003A3 true SK12452003A3 (sk) 2004-08-03

Family

ID=9912700

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1245-2003A SK12452003A3 (sk) 2001-04-11 2002-03-27 Derivát fenylheterocyklyléteru ako inhibítor reabsorpcie serotonínu, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje

Country Status (44)

Country Link
EP (1) EP1377550B9 (is)
JP (1) JP2005504728A (is)
KR (1) KR100570376B1 (is)
CN (1) CN1656072A (is)
AP (1) AP1543A (is)
AR (1) AR035818A1 (is)
AT (1) ATE281435T1 (is)
AU (1) AU2002244898B2 (is)
BG (1) BG108204A (is)
BR (1) BR0208812A (is)
CA (1) CA2443699A1 (is)
CZ (1) CZ20032677A3 (is)
DE (1) DE60201819T2 (is)
DO (1) DOP2002000371A (is)
EA (1) EA008936B1 (is)
EC (1) ECSP034802A (is)
EE (1) EE200300498A (is)
ES (1) ES2227448T3 (is)
GB (1) GB0109103D0 (is)
GE (1) GEP20053590B (is)
GT (1) GT200200071A (is)
HR (1) HRP20030824A2 (is)
HU (1) HUP0303880A2 (is)
IL (2) IL158141A0 (is)
IS (1) IS6960A (is)
MA (1) MA27010A1 (is)
MX (1) MXPA03009383A (is)
MY (1) MY136262A (is)
NO (1) NO20034525L (is)
NZ (1) NZ528481A (is)
OA (1) OA12500A (is)
PA (1) PA8543701A1 (is)
PE (1) PE20021003A1 (is)
PL (1) PL373533A1 (is)
PT (1) PT1377550E (is)
RS (1) RS79703A (is)
SI (1) SI1377550T1 (is)
SK (1) SK12452003A3 (is)
SV (1) SV2003000981A (is)
TN (1) TNSN03090A1 (is)
UA (1) UA74430C2 (is)
UY (1) UY27250A1 (is)
WO (1) WO2002083643A1 (is)
ZA (1) ZA200307507B (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256085A1 (en) * 2001-04-06 2002-10-21 Smithkline Beecham Corporation Quinoline inhibitors of hyak1 and hyak3 kinases
PT2208727E (pt) * 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
WO2006008635A1 (en) * 2004-07-14 2006-01-26 Pfizer Limited Process for the preparation of a 3-phenoxy-pyridine derivative
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
US8748627B2 (en) 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US7928243B2 (en) * 2006-12-21 2011-04-19 Abbott Laboratories Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
EP2114933B1 (en) 2007-01-04 2011-09-07 Prosidion Ltd Piperidine gpcr agonists
DE102008053242A1 (de) 2008-10-25 2010-05-06 Saltigo Gmbh Heteroaryl-Arylether
JP2014001199A (ja) * 2012-01-25 2014-01-09 Ishihara Sangyo Kaisha Ltd 有害生物防除剤
RU2019114940A (ru) 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US12240855B2 (en) 2019-03-06 2025-03-04 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU56301A (sh) * 1999-02-23 2004-05-12 Pfizer Products Inc. Inhibitori resorpcije monoamina za tretiranje poremećaja cns
CA2374898C (en) * 1999-05-21 2009-12-08 Biovitrum Ab Pyrazinyl-piperazine compounds, their use and preparation
SK4732002A3 (en) * 1999-10-13 2002-12-03 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors

Also Published As

Publication number Publication date
AU2002244898B2 (en) 2007-05-24
UY27250A1 (es) 2002-12-31
BR0208812A (pt) 2004-03-09
IL158141A0 (en) 2004-03-28
IS6960A (is) 2003-09-18
PL373533A1 (en) 2005-09-05
MA27010A1 (fr) 2004-12-20
TNSN03090A1 (fr) 2005-12-23
MY136262A (en) 2008-09-30
KR100570376B1 (ko) 2006-04-11
SI1377550T1 (en) 2005-02-28
RS79703A (sr) 2006-12-15
PE20021003A1 (es) 2002-11-12
EP1377550B1 (en) 2004-11-03
ATE281435T1 (de) 2004-11-15
NO20034525L (no) 2003-12-08
DOP2002000371A (es) 2002-10-15
HRP20030824A2 (en) 2005-08-31
AR035818A1 (es) 2004-07-14
EP1377550A1 (en) 2004-01-07
NZ528481A (en) 2006-02-24
SV2003000981A (es) 2003-07-29
BG108204A (bg) 2004-12-30
GEP20053590B (en) 2005-07-25
MXPA03009383A (es) 2004-01-29
NO20034525D0 (no) 2003-10-09
ECSP034802A (es) 2003-12-01
EA200300988A1 (ru) 2004-04-29
GT200200071A (es) 2003-01-31
WO2002083643A1 (en) 2002-10-24
EE200300498A (et) 2004-02-16
JP2005504728A (ja) 2005-02-17
ZA200307507B (en) 2004-11-19
HUP0303880A2 (hu) 2004-04-28
AP2002002468A0 (en) 2002-06-30
UA74430C2 (uk) 2005-12-15
DE60201819T2 (de) 2005-11-03
OA12500A (en) 2006-05-24
PA8543701A1 (es) 2004-05-26
DE60201819D1 (en) 2004-12-09
GB0109103D0 (en) 2001-05-30
CN1656072A (zh) 2005-08-17
CZ20032677A3 (cs) 2004-06-16
EP1377550B9 (en) 2005-11-23
AP1543A (en) 2006-01-11
CA2443699A1 (en) 2002-10-24
EA008936B1 (ru) 2007-10-26
IL158141A (en) 2007-10-31
KR20030088133A (ko) 2003-11-17
PT1377550E (pt) 2005-01-31
ES2227448T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
KR20100072266A (ko) 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
CN1469878A (zh) 用作hiv整合酶抑制剂的氮杂和多氮杂萘基羧酰胺类化合物
ES2243469T3 (es) Compuestos de eter difenilico utiles en terapia.
EP1377550B1 (en) Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
EP2718290A2 (en) Compositions and methods for modulating a kinase
BG107544A (bg) Производни на феноксибензиламин като селективни инхибитори на серотониново обратно поглъщане
JP2007505888A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
JP3204456B2 (ja) ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
AU2002244898A1 (en) Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
RU2444515C2 (ru) Производное амида индазолакриловой кислоты
US6630504B2 (en) Phenoxyphenylheterocyclyl derivatives as SSRIs
JP2008501775A (ja) オキシトシン拮抗剤としての置換トリアゾール誘導体
TW200404067A (en) New compounds
US6800652B2 (en) Diaryl compounds
US20030207857A1 (en) Phenyl heterocyclyl ethers
US6610747B2 (en) Phenoxybenzylamine derivatives as SSRIs
JP2009504628A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
WO2018168894A1 (ja) 重水素化ベンズイミダゾール化合物およびその医薬用途
MXPA05001834A (es) Compuestos de diarilo.
JPWO1996006084A1 (ja) 新規なキノリルアミン誘導体、その製造方法及び抗不整脈剤としての用途
JPH0378399B2 (is)

Legal Events

Date Code Title Description
FD9A Suspended procedure due to non-payment of fee